Selecting the Optimal Treatment Line for CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Breast Cancer. (2026). Voprosy Onkologii, 72(3), OF-2455. https://doi.org/10.37469/0507-3758-2026-72-3-OF-2455